By Lina carolina 
Basal cell carcinomas (BCCs), the most prevalent form of skin cancer, predominantly manifest in areas subjected to chronic sun exposure, such as the face. While often manageable, locally advanced BCCs can present significant therapeutic challenges, particularly concerning surgical intervention. A groundbreaking study conducted by a collaborative research team from MedUni Vienna and University Hospital Vienna has unveiled compelling evidence for the efficacy of a novel therapeutic approach, utilizing Talimogene Laherparepvec (TVEC), a genetically engineered oncolytic virus. The findings, published in the prestigious journal Nature Cancer, indicate that TVEC treatment led to tumor size reduction in all participating patients, facilitating less invasive surgical procedures and, in some cases, achieving complete tumor regression.
Understanding Basal Cell Carcinoma and the Need for Advanced Therapies
Basal cell carcinoma arises from the uncontrolled proliferation of basal cells, which are found in the epidermis, the outermost layer of the skin. These cancers are strongly linked to ultraviolet (UV) radiation exposure from the sun and artificial sources like tanning beds. While BCCs are generally slow-growing and rarely metastasize, their location, particularly on the face, can lead to significant cosmetic and functional impairments if extensive surgery is required. Current treatment modalities for BCCs include surgical excision, Mohs surgery (a specialized technique for precise tumor removal), topical chemotherapy, radiation therapy, and photodynamic therapy. However, for BCCs that are large, deeply invasive, or located in cosmetically sensitive areas, these standard treatments may not always yield optimal outcomes, often necessitating complex reconstructive surgery, such as skin grafts or flap procedures, to restore both form and function.
The challenge of treating locally advanced BCCs, where the tumor has grown deeply or extensively, underscores the critical need for innovative therapies that can shrink or eliminate these tumors prior to definitive surgical removal. This is precisely the area where the MedUni Vienna and University Hospital Vienna study has made significant strides.
The Novel Approach: Talimogene Laherparepvec (TVEC)
The cornerstone of this new therapeutic strategy is Talimogene Laherparepvec (TVEC), a modified herpes simplex virus type 1 (HSV-1). While TVEC has previously received regulatory approval for the treatment of unresectable melanoma metastases, its application in BCC represents a novel and promising advancement. TVEC is designed to selectively infect and replicate within tumor cells, leading to their lysis, or bursting. Crucially, this process also releases tumor-associated antigens, which then stimulate a localized anti-tumor immune response. This dual mechanism – direct tumor cell destruction and immune system activation – is what makes TVEC a powerful therapeutic agent.
The primary objective of the study was to employ TVEC as a neoadjuvant therapy, meaning it was administered before the planned surgical intervention. The goal was to reduce the tumor burden, thereby simplifying the surgical procedure and minimizing the risk of functional or cosmetic deficits for the patients. This strategy aims to preserve vital structures, reduce the extent of tissue removal, and potentially avoid the need for complex reconstructive techniques.
Study Design and Patient Cohort
The clinical trial enrolled 18 patients diagnosed with basal cell carcinoma that was deemed to be locally advanced. These individuals would have typically required a flap or skin graft due to the size and specific location of their tumors. The study protocol involved a series of six intralesional injections of TVEC, administered directly into the tumor site. These injections were delivered over a 13-week period, followed by surgical removal of the tumor. This phased approach allowed researchers to assess the impact of TVEC on tumor reduction and immune response before the final surgical intervention.
Promising Results: Tumor Reduction and Complete Regression
The outcomes of the study have been exceptionally encouraging. According to the principal investigator, Christoph Höller, Head of the Skin Tumour Centre at the Department of Dermatology, the results surpassed expectations. In half of the participating patients, TVEC therapy successfully reduced the tumor size to such an extent that direct wound closure was achievable during surgery, eliminating the need for more invasive reconstructive procedures. Furthermore, in a significant subset of patients, approximately one-third, subsequent histological examination of the removed tissue revealed no detectable living tumor cells, indicating a complete pathological response to the therapy.
Critically, every patient in the study experienced a reduction in tumor size, and importantly, no tumor progression was observed during the TVEC treatment period. This consistent efficacy across all participants highlights the robust nature of the therapy. The treatment was also reported to be well-tolerated by the patients, a vital consideration for any new therapeutic intervention.
Julia Ressler, the first author of the study and also from the Department of Dermatology, emphasized the clinical implications of these findings. She stated, "The new treatment option for basal cell carcinoma can not only simplify surgery, but also help to avoid disfiguring operations and functional limitations." This sentiment underscores the transformative potential of TVEC in improving the quality of life for patients undergoing treatment for this common skin cancer.
Immune System Activation: A Deeper Understanding
Beyond the clinical observations of tumor shrinkage, the research team, in collaboration with the St. Anna Children’s Hospital, conducted comprehensive analyses to investigate the underlying mechanisms of TVEC’s effectiveness. These in-depth investigations revealed that the therapy significantly strengthens the immune defense within the tumor tissue. By causing tumor cells to release antigens, TVEC effectively flags the cancer for the immune system, priming it to recognize and attack the malignant cells. This immune-mediated component of the therapy is crucial, as it not only contributes to the immediate tumor destruction but also potentially primes the body for long-term surveillance against any residual or recurring cancer cells. The detailed immunological profiling provides a scientific foundation for the observed clinical benefits and opens avenues for further optimizing such immunotherapies.
Implications for Neoadjuvant Therapy and Future Research
The published results position TVEC as a highly promising candidate for neoadjuvant treatment of basal cell carcinoma, particularly for patients who are not ideal candidates for extensive surgery due to the risks associated with larger procedures or the potential for severe cosmetic or functional consequences. The ability to pre-treat and shrink tumors could revolutionize the management of locally advanced BCCs, offering a less burdensome and more effective pathway to cure.
The study’s findings are a significant step forward, but the researchers acknowledge the need for further investigation. The current study involved a relatively small cohort of 18 patients. Therefore, larger, multi-center clinical trials are planned to confirm these benefits in a broader patient population and to further refine treatment protocols. These future studies will aim to solidify TVEC’s role in the standard of care for BCC and explore its potential in combination with other therapeutic modalities to enhance outcomes even further.
The successful application of an oncolytic virus like TVEC in BCC treatment also has broader implications for the field of oncolytic virotherapy. It demonstrates the adaptability of these viral agents to various cancer types beyond melanoma, paving the way for their investigation in other challenging oncological indications. The ongoing research at MedUni Vienna and University Hospital Vienna exemplifies a commitment to pushing the boundaries of cancer treatment and improving patient care through innovative scientific endeavors. The publication in Nature Cancer, a journal renowned for its rigorous peer review and high impact, attests to the scientific merit and significance of this research.
